We are live on ! Find out more
LEGN icon

Legend Biotech

20.68 USD
-0.62
2.91%
At close Updated Aug 26, 4:00 PM EDT
Pre-market
After hours
20.72
+0.04
0.19%
1 day
-2.91%
5 days
-8.78%
1 month
7.32%
3 months
-29.97%
6 months
7.26%
Year to date
-3.86%
1 year
-41.05%
5 years
-43.96%
10 years
-44.11%
 

About: Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

Employees: 3,200

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 45%
Neutral 50%
Negative 5%
Positive
Seeking Alpha
14 days ago
Legend's Pipeline Is Starting To Matter
Legend Biotech is transitioning from a capital-intensive biotech to a profitable, CARVYKTI-driven commercial cell therapy company. Q2 results highlight 52% YoY revenue growth, strong international CARVYKTI momentum, and a swing to $57.7M operating income, signaling sustainable profitability. CARVYKTI's 50% YoY sales growth is driven by earlier-line adoption and global expansion, with over 70% use now in 2L–4L settings.
Legend's Pipeline Is Starting To Matter
Neutral
Seeking Alpha
15 days ago
Legend Biotech Corporation (LEGN) Q2 2026 Earnings Call Transcript
Legend Biotech Corporation (LEGN) Q2 2026 Earnings Call Transcript
Legend Biotech Corporation (LEGN) Q2 2026 Earnings Call Transcript
Positive
24/7 Wall Street
15 days ago
Legend Biotech Gains 6% on Q2 Earnings Beat as Adjusted EPS Doubles Consensus
Shares of Legend Biotech (NASDAQ:LEGN | LEGN Price Prediction) are climbing 6% to $21.88 Tuesday midday after the company reported Q2 2026 results that paired a solid revenue beat with the first quarter of company-wide profitability in its history.
Legend Biotech Gains 6% on Q2 Earnings Beat as Adjusted EPS Doubles Consensus
Positive
MarketBeat
15 days ago
Legend Biotech Q2 Earnings Call Highlights
Legend Biotech NASDAQ: LEGN reported second-quarter 2026 results marked by continued global growth for CARVYKTI and the company's first quarter of company-wide profitability on both an IFRS and adjusted basis, management said during its earnings call.
Legend Biotech Q2 Earnings Call Highlights
Positive
Benzinga
22 days ago
Top 3 Health Care Stocks You'll Regret Missing This Quarter
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Top 3 Health Care Stocks You'll Regret Missing This Quarter
Neutral
GlobeNewsWire
1 month ago
Legend Biotech Announces CEO Transition
BRIDGEWATER, N.J., July 27, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech” or the “Company”), a global leader in cell therapy, today announced that Ying Huang, Ph.D., has stepped down as Chief Executive Officer and as a member of the Board of Directors, effective as of July 24, 2026. Dr. Huang will remain as an advisor through August to support a smooth transition.
Legend Biotech Announces CEO Transition
Positive
Seeking Alpha
1 month ago
Legend Biotech: Why I'm Ready To Go Long Again
On July 15, J&J, a Legend Biotech Corporation partner, announced continued strong demand for Carvykti. Sales of this CAR-T cell therapy were $657 million in the second quarter, up 10.1% quarter-on-quarter and 49.7% year-on-year. Legend hasn't yet announced when it will publish its second-quarter report, but given Carvykti's sales, I expect it to beat consensus estimates.
Legend Biotech: Why I'm Ready To Go Long Again
Positive
Benzinga
1 month ago
Top 3 Health Care Stocks That May Rocket Higher In July
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Top 3 Health Care Stocks That May Rocket Higher In July
Negative
Benzinga
2 months ago
Legend Biotech, Sleep Number And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq futures gaining over 1% on Thursday.
Legend Biotech, Sleep Number And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Neutral
GlobeNewsWire
2 months ago
Legend Biotech Corporation Announces Pricing of Public Offering
BRIDGEWATER, N.J., June 17, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech” or the “Company”), a global leader in cell therapy, today announced the pricing of an underwritten public offering of 7,700,000 American Depositary Shares (“ADSs”), each representing two ordinary shares of the Company, at a public offering price of $29.35 per ADS. In addition, Legend Biotech has granted the underwriters a 30-day option to purchase up to an additional 1,155,000 ADSs at the public offering price, less underwriting discounts and commissions. All of the ADSs are being offered by Legend Biotech. The gross proceeds to Legend Biotech from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Legend Biotech, are expected to be approximately $226 million, excluding any proceeds from the exercise of the underwriters' option to purchase additional ADSs. The offering is expected to close on June 23, 2026, subject to customary closing conditions.
Legend Biotech Corporation Announces Pricing of Public Offering
Price charts implemented using Lightweight Charts™